BrainStorm Cell Therapeutics’ Adult Stem Cell Approach More Relevant than Embryonic Stem Cell Therapies
News Nov 29, 2007
BrainStorm Cell Therapeutics Inc. has announced that based on studies conducted to date, the Company’s adult stem cell therapies provide a safer approach at curing and treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells.
In addition to the well-known ethical/religious concerns associated with embryonic stem cell therapies, experts are greatly concerned with the risk of the development of teratomas (or cancer) in patients as a result of the usage of embryonic stem cells.
BrainStorm Cell Therapeutics is confident that its approach to stem cell treatments, using adult stem cells, eliminates this additional risk factor that embryonic stem cell treatments face. The Company expects that this will enable it to commercialize its products quickly than its competitors, which will allow patients to benefit from its technologies and therapies more promptly.
Recently, two teams of scientists reported that they had converted human skin cells into what appeared to be embryonic stem cells (iPS) without having to make or destroy an embryo. Although these cells seemingly quell the religious debate troubling the field of stem cell testing, authors admit that the cells induce teratomas formation.
While this study is still in an early stage of basic science, it will likely take many years to eradicate the threat of cancer induction. The practical aspects of a therapy involving autologous induced pluripotent stem cells (iPS) are not yet clear. It is well known that nearly a decade has passed from the embryonic stem cell breakthrough, and still, a therapy based on such cells is not yet close to the market.
“Upon learning of the skin cell news (iPS), our scientific team is even more confident that adult stem cell therapies will, with G-Ds help, reach the market faster than any other stem cell approach,” said Chaim Lebovits, President of BrainStorm Cell Therapeutics. “We are continuing to design and conduct various pre-clinical trials, preparing the Company for the Pre IND stage with the FDA.”